PAG
PAG to buy cinema business from Chinese property developer
PAG has agreed to acquire Shanghai Xingyi Cinema Management from Hong Kong-listed property developer Seazen for about CNY 1.4bn (USD 187m).
China secondaries: Willing sellers?
Few, if any, LPs are so desperate to divest China exposure that they will sell fund positions at any price. The main sticking point for secondary transactions is a disconnect on valuations
PAG buys Australian hospitality business from KKR
PAG has acquired Australian Venue, which owns a portfolio of pubs, bars, and restaurants across Australia, from KKR for more than AUD 1.4bn (USD 900m).
Australia's River Capital targets UK cake shop chain
River Capital, an Australian investment firm that owns speciality cake retailer The Cheesecake Shop, has been rebuffed by the board of UK-based Cake Box Holdings after submitting a buyout offer for the listed company.
PAG COO David Kim retires
David Kim, a partner and COO of PAG’s private equity division, has retired from the firm after 13 years.
PAG invests $200m in India's RK Pharma
PAG has invested USD 200m in RK Pharma, a US-headquartered generic drug maker with significant operations in India.
PAG cuts target size of Asia fund by one third
PAG has reduced the target size of its fourth pan-Asian buyout fund to USD 6bn from USD 9bn, according to Mergermarket, AVCJ's sister publication.
PAG's Shan emphasizes diversity, control in Asia private equity
Momentum has shifted towards geographically diversified pan-regional investors, control deals, and private markets following a decade dominated by China-centric funds, growth-stage technology plays, and public equities, Weijian Shan, chairman and CEO...
Asia buyouts: The case for control
Investors are looking to minimise external financial and macro risks and emphasise factors they can control – which means more buyouts, careful asset selection, and greater operational intensity
PAG invests $500m in China's iQiyi
PAG has invested USD 500m in China-based online video streaming platform iQiyi through a private placement of senior convertible notes.
PAG closes fifth credit fund on $2.6bn
PAG has closed its fifth pan-Asian private credit fund at the hard cap with USD 2.6bn. It is said to be the largest direct lending fund raised in the region to date.
Uncertainty prompts deal financing discipline – AVCJ Forum
Large-cap buyout investors told the AVCJ Private Equity & Venture Forum they are hesitating to underwrite higher returns as debt terms tighten in cloudier market conditions.
Australian GPs sell food businesses to PAG
PAG has acquired Australia-based Patties Foods and Vesco Foods, facilitating exits for Pacific Equity Partners (PEP) and Catalyst Investment Managers, respectively.
Deal focus: PAG goes back to the theme park
PAG returns to a historically fruitful niche with the acquisition of Japanese theme park operator Huis Ten Bosch. COVID-19 made the deal possible but remains a wildcard
PAG buys Japanese theme park for $722m
PAG has agreed to buy Huis Ten Bosch, a Japanese theme park best known for its recreations of idyllic European cityscapes, for an equity valuation of approximately JPY 100bn (USD 722m).
PAG buys majority stake in China solvents business
PAG has agreed to pay HKD 2.68bn (USD 340m) for a 51% interest in a solvents business under Hong Kong-listed petrochemical products manufacturer Yip’s Chemical.
PAG launches Asia renewables platform
PAG plans to commit more than USD 1bn to renewables over the next several years with the launch of a platform dedicated to the development, construction, and operation of projects in Asia.
Singapore-based Timothy Zee leaves PAG
Timothy Zee, a Singapore-based managing director with PAG whose primary responsibilities included deal sourcing and business development, has left the firm after 10 years.
PAG's Hong Kong IPO on hold amid weak market
Asia-focused private equity firm PAG has put its Hong Kong IPO on hold, three sources familiar with the situation told Mergermarket, AVCJ’s sister title.
PAG backs acquisition of India's Optimus Drugs
PAG has supported the acquisition of Optimus Drugs for an undisclosed sum alongside CX Partners and Samara Capital as part of a joint Indian pharmaceuticals platform play.